Biological assessment and MRI monitoring of the therapeutic efficacy of a monoclonal anti-T CD4 antibody in multiple sclerosis patients

Multiple Sclerosis

Volumn 1, Issue 4, 1996, Pages 207-212

  Rumbach, L ^a   Racadot, E ^b   Armspach, J P ^c   Namer, I J ^c   Bonneville, J F ^a   Wijdenes, J ^d   Marescaux, C ^e   Herve, P ^b   Chambron, J ^c  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b Centre de Transfusion Sanguine

^c UNIVERSITÉ DE STRASBOURG   (France)

^d Diaclone Research   (France)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Anti T cell CD4 BF5 mAB; Cytokines; Monoclonal antibody; MRI; Multiple sclerosis (MS); Phase 1 open trial

Indexed keywords

CD4 ANTIGEN; MONOCLONAL ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; EVALUATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; LYMPHOCYTE SUBPOPULATION; MALE; METHODOLOGY; MONITORING; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RECURRENT DISEASE;

ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; ANTIGENS, CD4; DISEASE PROGRESSION; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTE SUBSETS; MAGNETIC RESONANCE IMAGING; MALE; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 0030072648     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/135245859600100404     Document Type: Article

References (28)

1. Ebers GC. (1994) The treatment of multiple sclerosis. Lancet 343: 275-279.
2. Hughes R. (1994) Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatr 57: 3-6.
3. Reingold SC. (1993) Advances in the understanding and treatment of multiple sclerosis. J Neuroimmunol 44: 221-224.
4. Weinshenker BG et al. (1991) An open trial of OKT3 in patients with multiple sclerosis. Neurology 41: 1047-1052.
5. Hodgkinson S et al. (1992) Phase I study of chimeric anti-D4 monoclonal antibody in multiple sclerosis. Neurology 42 (suppl. 3): P. 209, 242S.
6. Lindsey JW et al. (1994) Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis. Neurology 44: 413-419.
7. Lindsey JW et al. (1994) Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann Neurol 36: 183-189.
8. Rumbach L et al. (1994) Essai thérapeutique ouvert d'un anticorps monoclonal anti-T CD4 dans la sclérose en plaques. Rev Neurol 150: 418-424.
9. McDonald WI, Miller DH, Thompson AJ. (1994) Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-β. Ann Neurol 36: 14-18.
10. Paty DW, Li DKB, the UBC MS/MRI Study Group and the IFNβ Multiple Sclerosis Study Group. (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicentre, randomized, double-blind, placebo-controlled trial. Neurology 43: 662-667.
11. Racadot E, Wijdenes P, Wendling D. (1992) Immunological follow-up of 17 patients with rheumatoid arthritis treated in vivo with an anti-CD4 monoclonal antibody (BF5). Clin Exp Rhumatol 10: 365-374.
12. Racadot E et al. (1993) Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J Autoimmun 6: 771-786.
13. Hafler DA, Ritz F, Schlossman SF, Weiner HL. (1988). Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis, immunosuppressive effect and human anti-mouse responses. J Immunol 141: 131-138.
14. Moreau T et al. (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis. Lancet 344: 298-301.
15. Wendling D, Racadot E, Morel-Fourrier B, Wijdenes J. (1992) Treatment of rheumatoid arthritis with anti-CD4 monoclonal antibody. Open study of 25 patients with the BF5 clone. Clin Rheumatol 11: 542-547.
16. Ortho Multicenter Transplant Study Group. (1985) A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313: 337-341.
17. Van Snick JV. (1990) Interleukin-6 an overview. Annu Rev Immunol 8: 253-278.
18. Selmaj K, Raine CS. (1988) Tumor necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 23: 339-346.
19. Goodkin DE et al. (1992) Inter- and Intrarater scoring variability using grades 1.0-3.5 of the Kurtzke expanded disability status scale (EDSS). Neurology 42: 859-863.
20. Noseworthy JH, Vandervoort MK, Wong CJ, Ebers GC, and the Canadian Cooperative MS Study Group. (1990) Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 40: 971-975.
21. The IFNB Multiple Sclerosis Study Group. (1991) Interferon-beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43: 655-661.
22. Golberg D, Morel P, Chatenoud L, Boitard C. (1991) Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 4: 617-630.
23. Reiter C et al. (1991) Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151. Arthritis Rheum 34: 525-536.
24. Wendung D, Wijdenes J, Racadot E, Morel-Fourrier B. (1991) Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 18: 325-327.
25. Moreland LW et al. (1993) Use of a chimeric monoclonal anti-CD4 antibody in patients with refractory rheumatoid arthritis. Arthritis Rheum 36: 307-318.
26. Harris JO et al. (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29: 548-555.
27. McFarlan HF et al. (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32: 758-766.
28. Miller DH et al. (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatr 54: 683-688.